| [1] |
Osoba D, Zee B, Pater J, et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 1997, 15(1): 116-23.
|
| [2] |
Pollera CF, Giannarelli D. Prognostic factors influencing cisplatininduced emesis: definition and validation of a predictive logistic model[J]. Cancer, 1989, 64(5): 1117-22.
|
| [3] |
Booth CM, Clemons M, Dranitsaris G, et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study[J]. J Support Oncol, 2007, 5(8): 374-80.
|
| [4] |
Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets[J]. Neuropharmacology, 1996, 35 (8): 1121-9.
|
| [5] |
Huskey SE, Dean BJ, Bakhtiar R, et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets[J]. Drug Metab Dispos, 2003, 31(6): 785-91.
|
| [6] |
Bergström M, Hargreaves RJ, Burns HD, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant[J]. Biol Psychiatry, 2004, 55(10): 1007-12.
|
| [7] |
Van Laere K, De Hoon J, Bormans G, et al. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging[J]. Clin Pharmacol Ther, 2012, 92(2): 243-50.
|
| [8] |
Aapro MS, Schmoll HJ, Jahn F, et al. Cancer Treat Rev. Review of the efficacy of aprepitant for the prevention of chemotherapyinduced nausea and vomiting in a range of tumor types[J]. Cancer Treat Rev, 2013, 39(1):113-7.
|
| [9] |
Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin- -the Aprepitant Protocol 052 Study Group[J]. J Clin Oncol, 2003, 1( 22): 4112-9.
|
| [10] |
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin-America[J]. Cancer, 2003, 97(12): 3090-8.
|
| [11] |
Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy[J]. J Clin Oncol, 2005, 23(12): 2822-30.
|
| [12] |
Hu W, Fang J, Nie J, et al. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails[J]. Cancer Chemother Pharmacol， 20 14, 73(6): 1129-36.
|
| [13] |
Uchino J, Hirano R, Tashiro N, et al. Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy[J]. Asian Pac J Cancer Prev, 2012, 3(8): 4187-90.
|
| [14] |
Rapoport BL. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region[J]. Curr Med Res Opin, 2014, 30(9): 1857-81.
|
| [15] |
Gan, TJ, Apfel CC, Kovac A, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting[J]. Anesth Analg, 2007, 104(5): 1082-9.
|
| [16] |
Muñoz M, Bernabeu-Wittel J, Coveñas R. NK-1 as a melanoma target[J]. Expert Opin Ther Targets, 2011, 15(7): 889-97.
|
| [17] |
Rangwala F, Zafar SY, Abernethy AP. Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach[J]. Curr Opin Support Palliat Care, 2012, 6(1): 69-76.
|
| [18] |
Ruhlmann CH, Herrstedt J. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting[J]. Expert Opin Drug Saf, 2011, 10(3): 449-62.
|
| [19] |
Takeshima N, Matoda M, Abe M, et al. Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase Ⅱ trial[J]. Support Care Cancer, 2014, 22(11): 2891-8.
|
| [20] |
McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone[J]. Clin Pharmacol Ther, 2003, 74(1): 17-24.
|
| [21] |
Maie K, Okoshi Y, Takaiwa N, et al. Aprepitant does not alter prednisolone pharmacokinetics in patients treated with R-CHOP[J]. Ann Oncol, 2014, 25(1): 298-9.
|
| [22] |
Walko CM, Combest AJ, Spasojevic I，et al. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients[J]. Cancer Chemother Pharmacol, 2012, 69 (5): 1189-96.
|
| [23] |
Egerer G, Eisenlohr K, Gronkowski M, et al. The NK receptor antagonist aprepitant does not alter the pharmacokinetics of highdose melphalan chemotherapy in patients with multiple myeloma [J] Br J Clin Pharmacol, 2010, 70(6): 903-7.
|
| [24] |
Kaneta T, Fujita K, Akiyama Y, et al. No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion[J]. Cancer Chemother Pharmacol, 20 14, 74(3): 539-47.
|
| [25] |
Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatininduced emesis[J]. Eur J Cancer, 2001, 37(7): 835-42.
|
下载:
